MYGN
Myriad Genetics Inc
NASDAQ: MYGN · HEALTHCARE · DIAGNOSTICS & RESEARCH
$3.17
+4.97% today
Updated 2026-08-04
Market cap
$514.74M
P/E ratio
—
P/S ratio
0.92x
EPS (TTM)
$-4.19
Dividend yield
—
52W range
$4 – $9
Volume
1.9M
Myriad Genetics Inc (MYGN) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$3.17
12-Month target
—
2030 Target
—
Intrinsic (DCF)
$46.12
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.7B | $0.7B | $0.8B | $0.8B | $0.8B | $0.9B | $1.0B | $1.0B | $1.1B |
| EPS | — | — | — | — | — | — | — | — | — |
CAGR applied: 8.16% (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -41.30%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.